Partner Hospitals

Founded in 1964, it is a benchmark for cancer diagnosis and treatment in South China. Annual outpatient and emergency visits reach 2.558 million, and annual inpatient admissions are 222,000. Its medical volume ranks among the top of national oncology-specialized hospitals. It boasts leading medical technologies and an Asia-class radiotherapy center with top-tier hardware and software. Minimally invasive robotic surgeries are performed in multiple specialties. The hospital maintains cooperation with The University of Texas MD Anderson Cancer Center, which ranks No.1 among oncology centers in the United States.

Founded in 1931. It is equipped with 22 high-end medical devices including Da Vinci surgical robots, MR Linac, TOMO, LA, PET-CT, PET-MR and 5.0T MRI. Annual outpatient visits: 2.5 million; annual inpatient admissions: 170,000; annual surgeries: 80,000; annual radiotherapy sessions: 420,000. The overall 5-year survival rate of patients with malignant tumors reaches 72%.

Founded in 1920. It is the supporting institution for the National Center for Stomatology and the National Clinical Research Center for Oral Diseases. Its Department of Plastic and Reconstructive Surgery remains the world’s largest plastic surgery medical center and China’s leading center for plastic surgery in medical treatment, teaching and research. Annual outpatient and emergency visits exceed 4.8 million, inpatient admissions over 150,000, inpatient surgeries more than 90,000, and outpatient surgical procedures over 170,000.

Founded in 1957, it is China’s first Grade A tertiary specialized hospital focusing on the diagnosis and treatment of cardiothoracic diseases after the founding of the People’s Republic of China. Centered on two major discipline clusters: thoracic tumors and cardiovascular diseases, it masters the most extensive spectrum and full range of diagnostic and therapeutic technologies for cardiothoracic diseases in China. Annual outpatient and emergency visits exceed 860,000, with more than 28,000 surgeries performed each year. The proportion of Grade-III and Grade-IV surgeries is over 90%. Its surgical volume for tracheal and mediastinal tumors ranks No.1 nationwide, lung tumor surgery volume ranks No.2 nationwide, and esophageal surgery volume is among the top in China and ranks No.1 in the city.

Founded in 1869, the hospital has set national benchmarks including the “Hangzhou Protocol” for transcatheter heart valve replacement, minimally invasive complex cataract surgery, standardized diagnosis and treatment of colorectal tumors, and mass severe trauma rescue. The perioperative survival rate of pediatric liver transplantation is at the internationally leading level.

Founded in 1892, it has reached leading domestic and international standards in many fields, such as adult living donor liver transplantation, early diagnosis and treatment of lung cancer, cardiac interventional therapy, neurosurgery and functional neurosurgery, integrated traditional Chinese and Western medicine for severe pancreatitis, and allogeneic combined larynx-trachea-thyroid transplantation.

Founded in 1937. Its clinical capabilities in the fields of heart, liver, kidney, lung, digestive tract and panvascular diseases are at the top domestic and world-advanced level. The hospital is fully equipped with world-class diagnostic and therapeutic equipment including Da Vinci surgical robots, 3.0T high-field MRI, PET-CT, high-end DSA interventional systems and precision radiotherapy devices. More than 90 MDT teams have been established. Annual outpatient and emergency visits exceed 6.1 million, inpatient admissions over 280,000, and inpatient surgeries more than 210,000.